nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 29th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_UNDER_1M
|
Cambridge, MA
|
Richard Murray Ph.D
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 29th, 2022 12:09PM
|
Aug 29th, 2022 12:09PM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 28th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_UNDER_1M
|
Cambridge, MA
|
Richard Murray Ph.D
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 28th, 2022 05:07AM
|
Aug 28th, 2022 05:07AM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 27th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_UNDER_1M
|
Cambridge, MA
|
Richard Murray Ph.D
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 27th, 2022 04:27AM
|
Aug 27th, 2022 04:27AM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 25th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_UNDER_1M
|
Cambridge, MA
|
Richard Murray Ph.D
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 25th, 2022 09:07AM
|
Aug 25th, 2022 09:07AM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 23rd, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_25M_100M
|
780 Memorial Drive Cambridge, MA 02139
|
RICHARD MURRAY, PH.D.
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 23rd, 2022 11:00AM
|
Aug 23rd, 2022 11:00AM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 21st, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_25M_100M
|
780 Memorial Drive Cambridge, MA 02139
|
RICHARD MURRAY, PH.D.
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 21st, 2022 12:44PM
|
Aug 21st, 2022 12:44PM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 20th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_25M_100M
|
780 Memorial Drive Cambridge, MA 02139
|
RICHARD MURRAY, PH.D.
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 20th, 2022 02:21PM
|
Aug 20th, 2022 02:21PM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 19th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_25M_100M
|
780 Memorial Drive Cambridge, MA 02139
|
RICHARD MURRAY, PH.D.
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 19th, 2022 12:44PM
|
Aug 19th, 2022 12:44PM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 18th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_25M_100M
|
780 Memorial Drive Cambridge, MA 02139
|
RICHARD MURRAY, PH.D.
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 18th, 2022 04:28AM
|
Aug 18th, 2022 04:28AM
|
Jounce Therapeutics
|
|
|
nasdaq:jnce
|
https://www.indeed.com/cmp/jounce-therapeutics
|
Aug 17th, 2022 12:00AM
|
Open
|
Jounce Therapeutics
|
|
Pharmaceutical & Biotechnology
|
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
|
RRv1_25M_100M
|
780 Memorial Drive Cambridge, MA 02139
|
RICHARD MURRAY, PH.D.
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
5.00
|
4.20
|
3.80
|
4.00
|
4.00
|
3.80
|
|
|
|
|
|
|
|
|
|
Aug 17th, 2022 10:06AM
|
Aug 17th, 2022 10:06AM
|
Jounce Therapeutics
|
|
|